News - Roche, Oncology

Filter

Current filters:

RocheOncology

Popular Filters

1 to 25 of 189 results

Currency takes toll on Roche first-half results

Currency takes toll on Roche first-half results

24-07-2014

Swiss pharma major Roche, the world’s leading oncology company, this morning posted first-half 2014…

FinancialOncologyPharmaceuticalRocheSwitzerland

SMC guidance on AstraZeneca’s diabetes drug and Roche’s MabThera

SMC guidance on AstraZeneca’s diabetes drug and Roche’s MabThera

08-07-2014

The Scottish Medicines Consortium (SMC) has issued guidance on Anglo-Swedish drug major AstraZeneca’s…

AstraZenecaBiotechnologydapagliflozinDiabetesMabTheraOncologyRocheUK

Japan first to approve Roche’s lung cancer drug alectinib

Japan first to approve Roche’s lung cancer drug alectinib

04-07-2014

The Japanese Ministry of Health, Labor and Welfare has approved Swiss pharma major Roche’s alectinib…

alectinibJapanOncologyPharmaceuticalRegulationRoche

Roche to acquire Seragon in deal that could reach over $1.7 billion

Roche to acquire Seragon in deal that could reach over $1.7 billion

02-07-2014

Swiss drug major Roche says its USA-based biotech subsidiary Genentech has entered into a definitive…

BiotechnologyGenentechMergers & AcquisitionsOncologyRocheSeragon Pharmaceuticals

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows

30-06-2014

Merck Serono, the biotech subsidiary of Germany’s Merck KGaA, has released positive new clinical trial…

AvastinBiotechnologyErbituxMerck KGaAMerck SeronoOncologyResearchRoche

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

Benefits of Herceptin outweigh the risk of harm in advanced breast cancer

Benefits of Herceptin outweigh the risk of harm in advanced breast cancer

12-06-2014

In women with advanced (or metastatic) breast cancer, treatment with the breast cancer drug trastuzumab,…

HerceptinOncologyPharmaceuticalResearchRochetrastuzumab

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

10-06-2014

Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex…

BiosimilarsBrazilJohnson & JohnsonMabTheraMexicoOncologyPharmaceuticalPricingRocheVelcade

ASCO 2014: Takeda, Roche and Celgene present results

ASCO 2014: Takeda, Roche and Celgene present results

02-06-2014

A host of results have been presented by global pharma majors at the 2014 Annual Meeting of the American…

AbraxaneCelgeneOncologyPharmaceuticalResearchRocheTakeda PharmaceuticalsUSAVelcade

CHMP recommends approval of Roche’s Gazyvaro for CLL

25-05-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)had recommended…

EuropeGazyvaroobinutuzumabOncologyPharmaceuticalRegulationRoche

Biocad’s AcellBia is first MAb biosimilar approved by Russia’s Ministry of Health

15-05-2014

A biosimilar of Swiss drug major Roche’s MabThera (rituximab), to be marketed under the trade name…

AcellBiaBiocadBiosimilarsGenericsMabTheraOncologyRegulationRocheRussia

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

Roche may lose $240 million contract in Russia to Biocad biosimilar

Roche may lose $240 million contract in Russia to Biocad biosimilar

07-05-2014

Swiss drug major Roche may lose an important $240 million contract in Russia for the supply of its anti-cancer…

AcellBiaBiocadBiosimilarsBiotechnologyMabTheraMarkets & MarketingOncologyRegulationrituximabRoche

UK’s NICE rejects use of Roche’s Kadcyla for breast cancer on NHS

23-04-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today issued preliminary…

KadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

EMA says that vials of falsified Herceptin have been identified

EMA says that vials of falsified Herceptin have been identified

16-04-2014

The European Medicines Agency says it has been informed that vials of Swiss drug major Roche’s blockbuster…

EuropeHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

07-04-2014

Swiss drug major Roche has entered to a worldwide collaboration with Spanish functional genomics firm…

BiotechnologyIQuumLicensingMergers & AcquisitionsOncologyORY-1001Oryzon GenomicsRoche

Pharmaceutical companies to benefit from new blood cancer drugs

04-04-2014

Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years,…

AmgenCelgeneGilead SciencesJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRoche

1 to 25 of 189 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top